ADVM - Adverum Biotechnologies, Inc.

QQQ $ 479.76 $ 5.15 (1.08 %)

DIA $ 411.97 $ 4.35 (1.07 %)

SPY $ 562.00 $ 5.91 (1.06 %)

TLT $ 98.37 $ 0.64 (0.65 %)

GLD $ 231.99 $ 2.65 (1.16 %)

Previous Close

$ 7.32

Open

Bid

$ 7.28 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 6.38 - $ 29.70

Volume

114,356

Average Volume

Market Cap

152.26M

Beta (5Y Monthly)

$ 1.23

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	03-18-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-11-2023	03-31-2023	10-Q
7	03-30-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-11-2022	06-30-2022	10-Q
10	05-12-2022	03-31-2022	10-Q
11	03-29-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-28-2020	03-31-2020	10-Q
19	03-12-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	03-06-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-06-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-08-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	03-09-2017	12-31-2016	10-K
32	11-08-2016	09-30-2016	10-Q
33	08-09-2016	06-30-2016	10-Q
34	05-06-2016	03-31-2016	10-Q
35	03-04-2016	12-31-2015	10-K
36	11-09-2015	09-30-2015	10-Q
37	08-13-2015	06-30-2015	10-Q
38	05-13-2015	03-31-2015	10-Q
39	03-05-2015	12-31-2014	10-K
40	11-12-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Maintains Buy on Adverum...
08/14/2024 13:57:04

Truist Securities analyst Joon Lee maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and lowers the price target fr...

HC Wainwright & Co. Reiterates Buy on Adve...
08/13/2024 18:20:28

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

RBC Capital Maintains Sector Perform on Ad...
08/13/2024 16:26:53

RBC Capital analyst Luca Issi maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Sector Perform and lowers the price tar...

Adverum Biotechnologies Q2 2024 Adj EPS $(...
08/12/2024 20:18:59

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate ...

around-88m-bet-on-nextdecade-check-out-these-3-stocks-insiders-are-buying

Around $88M Bet On NextDecade? Check Out T...
08/01/2024 12:47:22

Adverum Biotechnologies Announces FDA RMAT...
08/01/2024 12:12:27

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...

more-than-10m-bet-on-appian-check-out-these-3-stocks-insiders-are-buying

More Than $10M Bet On Appian? Check Out Th...
07/19/2024 17:17:07

Chardan Capital Maintains Buy on Adverum B...
07/18/2024 21:12:36

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy, adjusts target to $40 fr...

adverum-releases-interim-data-from-gene-therapy-study-for-blindness-disorder-prepares-for-pivotal-study

Adverum Releases Interim Data From Gene Th...
07/17/2024 18:54:36

Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed ...

why-aslan-pharmaceuticals-shares-are-trading-lower-by-over-38-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why ASLAN Pharmaceuticals Shares Are Tradi...
07/17/2024 17:28:51

why-bloom-energy-group-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket

Why Bloom Energy Group Shares Are Trading ...
07/17/2024 10:03:31

Adverum Biotechnologies Reveals 26-Week In...
07/17/2024 06:50:55

6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-...

Adverum Biotechnologies Hosts Webcast To R...
07/10/2024 12:14:04

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...

Oppenheimer Initiates Coverage On Adverum ...
06/25/2024 12:31:48

Oppenheimer analyst Francois Brisebois initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Outperform rating ...

Truist Securities Maintains Buy on Adverum...
05/15/2024 18:21:35

Truist Securities analyst Joon Lee maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $60 price target.

HC Wainwright & Co. Reiterates Buy on Adve...
05/10/2024 12:32:57

HC Wainwright & Co. analyst Matthew Caufield reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $...

Adverum Biotechnologies Q1 2024 Adj EPS $(...
05/09/2024 21:21:42

Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimat...

HC Wainwright & Co. Initiates Coverage On ...
04/30/2024 10:09:10

HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Adverum Biotechnologies (NASDAQ:ADVM) with a Buy rati...

Mizuho Maintains Buy on Adverum Biotechnol...
04/29/2024 11:33:34

Mizuho analyst Graig Suvannavejh maintains Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and lowers the price target from...

Adverum Biotechnologies To Present LUNA 26...
04/25/2024 20:40:03

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of c...